3.04
-0.07(-2.25%)
Currency In USD
| Previous Close | 3.11 |
| Open | 3.12 |
| Day High | 3.15 |
| Day Low | 3.02 |
| 52-Week High | 4.08 |
| 52-Week Low | 1.24 |
| Volume | 4.34M |
| Average Volume | 4.77M |
| Market Cap | 806.04M |
| PE | -16.89 |
| EPS | -0.18 |
| Moving Average 50 Days | 3.66 |
| Moving Average 200 Days | 2.5 |
| Change | -0.07 |
If you invested $1000 in Akebia Therapeutics, Inc. (AKBA) 10 years ago, it would be worth $481.01 as of August 20, 2025 at a share price of $3.04. Whereas If you bought $1000 worth of Akebia Therapeutics, Inc. (AKBA) shares 5 years ago, it would be worth $280.44 as of August 20, 2025 at a share price of $3.04.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference
GlobeNewswire Inc.
Aug 06, 2025 12:00 PM GMT
CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executi
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization
GlobeNewswire Inc.
Aug 04, 2025 12:00 PM GMT
VOCAL, an open-label active-controlled study, is being conducted at DaVita dialysis clinics to evaluate benefits of treating patients with Vafseo three times a weekCAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasd
Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights
GlobeNewswire Inc.
Jul 31, 2025 12:00 PM GMT
Akebia to Host Conference Call on August 7, 2025, at 8:00 a.m. EDTCAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the second quarter ended June